WO2004076473A2 - Peptides interagissant avec le recepteur androgne - Google Patents

Peptides interagissant avec le recepteur androgne Download PDF

Info

Publication number
WO2004076473A2
WO2004076473A2 PCT/US2004/003774 US2004003774W WO2004076473A2 WO 2004076473 A2 WO2004076473 A2 WO 2004076473A2 US 2004003774 W US2004003774 W US 2004003774W WO 2004076473 A2 WO2004076473 A2 WO 2004076473A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
polypeptide
group
peptides
Prior art date
Application number
PCT/US2004/003774
Other languages
English (en)
Other versions
WO2004076473A3 (fr
Inventor
Benjamin M. Buehrer
Thomas R. Barnett
Original Assignee
Karo Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio Ab filed Critical Karo Bio Ab
Publication of WO2004076473A2 publication Critical patent/WO2004076473A2/fr
Publication of WO2004076473A3 publication Critical patent/WO2004076473A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Definitions

  • the present invention is directed to interacting peptides, and in particular to peptides that interact with the androgen receptor ("AR").
  • AR androgen receptor
  • ligand modulators for androgen receptor activity.
  • these ligand modulators are steroidal or non-steroidal small molecules that act as agonists, partial agonists, and antagonists for the androgen receptor (AR).
  • AR androgen receptor
  • U.S. Patent No. 6,462,038 issued to Higuchi et al. discloses non- steroidal compounds that are modulators (i.e. agonists and antagonists) of androgen receptors, and to methods for the making and use of such compounds.
  • U.S. Patent No. 6,492,554 issued to Dalton et al.
  • Therapeutic peptides have been shown to be useful in a variety of ways in the biological and therapeutic arts.
  • Therapeutic peptides are becoming a part of the standard regimen for treating conditions such as prostate cancer, endometriosis, and acromegaly.
  • Therapeutic peptides may be used to treat a variety of diseases including HTV, hepatitis B, and various types of cancer.
  • U.S. Patent No. 6,465,431 to Thorn et al. discloses a therapeutic peptide consisting of fragments of troponin C, troponin I, troponiii T, which are effective to inhibit angiogenesis. Chang and McDonnell (Mol Endocrinol.
  • Identification of peptides that bind to AR are desirable to understanding its mode of action and as potential modulators of AR activity. Accordingly, there is a need in the art to identify and provide peptides that bind to the androgen receptor, and that could influence the response of AR and be utilized as therapeutic treatments for AR-based diseases. The present invention is believed to be an answer to that need.
  • the present invention is directed to a polypeptide that binds to the androgen receptor, the polypeptide comprising the amino acid sequence Ar-X-X-Z-Ar, wherein Ar is an aromatic amino acid; X is any amino acid; and Z is a hydrophobic amino acid ( ⁇ ) or an aromatic amino acid (Ar).
  • the present invention is directed to a polypeptide that binds to the androgen receptor, the polypeptide comprising the amino acid sequence Ser- ⁇ -Ar-X- ⁇ - ⁇ -Ar, wherein Ar is an aromatic amino acid; X is any amino acid; ⁇ is a hydrophobic amino acid; ⁇ is a basic amino acid; and ⁇ is an acidic amino acid.
  • the present invention is directed to a polypeptide that binds to the androgen receptor, the polypeptide comprising the amino acid sequence Ser- ⁇ -Ar- ⁇ - X- ⁇ -Ar, wherein Ar is an aromatic amino acid; X is any amino acid; ⁇ is a hydrophobic amino acid; ⁇ is a basic amino acid; and ⁇ is an acidic amino acid.
  • the present invention is directed to a polypeptide that binds to the androgen receptor, the polypeptide comprising the amino acid sequence Ser-X-Ar-X- X- ⁇ -Ar, wherein Ar is an aromatic amino acid; X is any amino acid; and ⁇ is a hydrophobic amino acid.
  • the present invention is directed to methods of analyzing the surface conformation of a protein using one or more of the above polypeptide sequences; methods of identifying modulators of protein function using one or more of the above polypeptide sequences; pharmaceutical compositions comprising a pharmaceutically acceptable carrier and one or more of the above polypeptide sequences; and methods of treatment and/or diagnosis of diseases utilizing the above peptides or polypeptides.
  • Figure 1 Panel A, shows a binding curve of peptide 2554 concentration versus fluorescence signal at various concentrations of androgen receptor;
  • Figure 1 Panel B, shows a binding curve of peptide 2582 concentration versus fluorescence signal at various concentrations of androgen receptor;
  • Figure 1 Panel C, shows the results of a competition assay between peptide 2554 and various competitor peptides;
  • Figure 1 Panel D, shows the results of a competition assay between peptide 2582 and various competitor peptides
  • Panel A shows the binding curves of eight (8) peptides to androgen receptor with increasing concentrations of dihydrotestosterone
  • FIG. 2 Panel B, shows the binding curves of eight (8) peptides to androgen receptor with increasing concentrations of cyproterone acetate.
  • a peptide that binds to AR refers to a peptide that can interact with AR (or one or more of its domains) as monitored by standard methods such as: two-hybrid interaction in cells using a transcriptional reporter; modulation of AR activities such as AR mediated transcription, interaction with proteins, cellular localization, secondary protein modifications (phosphorylation, sumoylation, ubiquitinylation, etc.); co-immunoprecipitation (or modulation of such); direct interaction (FRET, BiaCore analysis, and the like); co-crystallization; or other methods well known in the art.
  • AR androgen receptor
  • the peptides of the present invention share several sequence and structural motifs that permit members of the peptide families to bind to the androgen receptor and possibly modulate its activity.
  • the general sequence for this family of peptides is
  • Ar is an aromatic amino acid (e.g., tryptophan, phenylalanine, tyro sine);
  • X is any amino acid;
  • Z is a hydrophobic amino acid ( ⁇ ) or an aromatic amino acid (Ar).
  • one preferred embodiment of the peptides of the present invention include a family of peptides having the general sequence
  • Ar-X-X- ⁇ -Ar wherein Ar is an aromatic amino acid (e.g., tryptophan, phenylalanine, and tyrosine); X is any amino acid; and ⁇ is a hydrophobic amino acid (e.g., valine, leucine, isoleucine, methionine, and the like). Examples of sequences having this general sequence include (using single-letter abbreviations for the amino acids):
  • Representative amino acid sequences containing these general sequences include SRWQALFDDGTDTSR (SEQ ID NO:5)
  • SSKFAALWDPPKLSR (SEQ ID NO:6)
  • SSAGGHGNKWAGLWRESR (SEQ ID NO:7)
  • SSTGIQSKFQALFSR (SEQ ID NO:8)
  • the peptides of the present invention have the general sequence
  • Ar-X-X-Ar-Ar wherein Ar is an aromatic amino acid (e.g., tryptophan, phenylalanine, tyrosine), and X is any amino acid.
  • Ar is an aromatic amino acid (e.g., tryptophan, phenylalanine, tyrosine), and X is any amino acid.
  • FQNFF (SEQ ID NO:9)
  • FHSFW (SEQ ID NO:10)
  • amino acid sequences containing these general sequences include SSFQNFFAAPYMESPLSSR (SEQ ID NO:13)
  • another family of peptides that bind to the androgen receptor has the general amino acid sequence
  • Ser- ⁇ -Ar-X- ⁇ - ⁇ -Ar wherein Ar is an aromatic amino acid; X is any amino acid; ⁇ is a hydrophobic amino acid; ⁇ is a basic amino acid (e.g., lysine, arginine, histidine, and the like); and ⁇ is an acidic amino acid (e.g., aspartic acid, glutamic acid, and the like).
  • X is any amino acid
  • ⁇ is a hydrophobic amino acid
  • ⁇ is a basic amino acid (e.g., lysine, arginine, histidine, and the like)
  • ⁇ is an acidic amino acid (e.g., aspartic acid, glutamic acid, and the like).
  • SKFYELF (SEQ ID NO: 17) SRFADIF (SEQ ID NO: 18) SRFSELF (SEQ ID NO: 19) SRFAELW (SEQ ID NO:20)
  • Representative amino acid sequences containing these general sequences include
  • SSKFYELFRNVNLSR SRFADIFREAQQESR (SEQ ID NO:22)
  • SRFSELFISPYPVPDGLSR SEQ ID NO:23
  • SRFAELWEMDWGELVDPSR SEQ ID NO:24
  • another family of peptides that bind to the androgen receptor has the general amino acid sequence
  • SRFDSLF (SEQ ID NO:25)
  • SRFEHLW (SEQ ID NO:26)
  • SRWESLW (SEQ ID NO:27)
  • amino acid sequences containing these general sequences include SRFDSLFGVWAGGEAMGSR (SEQ ID NO:29) SRFEHLWKYELTDSR (SEQ ID NO:30)
  • another family of peptides that bind to the androgen receptor has the general amino acid sequence
  • SPFYTLF SLFANRF (SEQ ID NO:36) Representative amino acid sequences containing these general sequences include SSNSLFQTMYLQGANFSSR(SEQ ID NO:37)
  • any of the peptides or polypeptides of the present invention may be labeled with a detectable label, for example, of radiolabels, fluorophores, chromophores, enzymes, and combinations thereof.
  • the present invention is also directed to a polypeptide that comprises at least 50% amino acid sequence identity to one or more of the disclosed polypeptides.
  • the present invention is also directed to a peptide or polypeptide that binds to the androgen receptor, wherein that binding is competitively inhibited by one or more of the disclosed peptides or polypeptides.
  • the present invention is also directed to a chimeric protein comprising one or more of the peptides or polypeptides disclosed herein, and at least a portion of a filamentous phage protein that is sufficient for integration of the chimeric protein into the coat of phage particles so as to display the polypeptide.
  • the present invention is also directed to a filamentous phage displaying a peptide or polypeptide disclosed herein.
  • the above peptides may be isolated by themselves or in any combination.
  • the sequences may have additional amino acids attached to N-terminal or C- terminal portions of the sequence.
  • the peptides may be part of a larger polypeptide or protein.
  • the peptides may also form all or part of a peptidomimetic structure (e.g., non-natural peptides, cyclic peptides, peptide analogs, and constrained peptides).
  • the peptides and polypeptides of the present invention may be used in biological research and as therapeutics.
  • the peptides and polypeptides of the present invention can be utilized in multiple formats ranging from in vitro to cell culture systems, and may be used to identify novel AR modulators that affect AR mediated processes.
  • the peptides and polypeptides of the present invention are also useful as probes to determine different surface conformations induced by AR modulators, as ligands in the crystalization of AR, and as therapeutic agents to disrupt or enhance AR activity. Procedures for performing these operations are well known to those of skill in the art (See, Bledsoe, R. K. et al. Cell 110:93-105 (2002); Shiau, A. K. et al.
  • the peptides of the present invention are also useful as a panel for in vitro and in vivo classification of compounds. See, for example, International Patent Application WO 99/54728, hereby incorporated by reference in its entirety, which discloses use of peptides (termed "BioKeys") as probes for use in an investigation of alteration of receptor conformation.
  • the peptides of the present invention may also be used in a competitive displacement assay to identify modulators of receptor activity in a high-throughput screen; to fingerprint modulators of receptor activity and classify them as agonists or antagonists of receptor activity; or to identify the natural ligands of orphan receptors.
  • the peptides and polypeptides of the present invention are preferably part of pharmaceutical compositions generally comprising one or more of the peptides or polypeptides in combination with a pharmaceutically acceptable carrier.
  • a pharmaceutical composition is preferably administered internally, e.g., intravenously, in the form of conventional pharmaceutical preparations, for example in conventional enteral or parenteral pharmaceutically acceptable excipients containing organic and/or inorganic inert carriers, such as water, gelatin, lactose, starch, magnesium stearate, talc, plant oils, gums, alcohol, Vaseline, or the like.
  • the pharmaceutical preparations can be in conventional solid forms, for example, tablets, dragees, suppositories, capsules, or the like, or conventional liquid forms, such as suspensions, emulsions, or the like. If desired, they can be sterilized and/or contain conventional pharmaceutical adjuvants, such as preservatives, stabilizing agents, wetting agents, emulsifying agents, buffers, or salts used for the adjustment of osmotic pressure.
  • the pharmaceutical compositions may also contain other therapeutically active materials.
  • the pharmaceutical composition of the invention should include an amount of the peptide(s) or polypeptide(s) of the invention effective for desired activity.
  • the effective dosage will depend on the activity and toxicity of the particular peptide or peptides employed and is thus within the ordinary skill of the art to determine for any particular host mammal or other host organism. Suitable dosages may be, for example, in the range of about 0.5-100 mg per kg for a human being. Alternatively, the claimed peptides may be used to control the androgen receptor in vitro or may be used as a modulating agent in nonhuman mammals.
  • the present invention is also directed to a method of diagnosing a disease in a patient characterized by abnormal levels of activation of androgen receptor (AR) comprising (1) providing a sample of body fluid or tissue of said patient; (2) administering a diagnostically effective amount of the above pharmaceutical composition, and (3) assaying the amount of activated AR in said body fluid or tissue of said patient.
  • the present invention is also directed to a method for treating a patient suffering from a disease characterized by abnormal levels of activation of androgen receptor (AR), comprising administering to said patient a therapeutically effective amount of the above pharmaceutical composition.
  • One disease characterized by abnormal levels of activation of AR is prostate cancer.
  • diagnostic assays employ a binding molecule of known binding activity, or a conjugate or derivative thereof, as a diagnostic reagent.
  • the "binding molecule” may be a peptide, peptoid, peptidomimetic or other analogue of the present invention, or an oligonucleotide of the present invention, which binds the analyte or a binding partner of the analyte.
  • the analyte is a target protein.
  • In vitro assays may be diagnostic assays (using a known binding molecule to detect or measure an analyte) or screening assays (determining whether a potential binding molecule in fact binds a target).
  • diagnostic assays using a known binding molecule to detect or measure an analyte
  • screening assays determining whether a potential binding molecule in fact binds a target.
  • the format of these two types of assays is very similar and, while the description below refers to diagnostic assays for analytes, it applies, mutatis mutandis, to the screening of molecules for binding to targets.
  • the in vitro assays of the present invention may be applied to any suitable analyte-containing sample, and may be qualitative or quantitative in nature.
  • the assay In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the amount of the analyte).
  • SPS signal producing system
  • This signal is, or is derived from, one or more observable raw signals.
  • the raw signal for a particular state is the level of an observable parameter, or of a function dependent on the level(s) of one or more observable parameters.
  • the signal is a difference in raw signals, depending on the states to be differentiated by the assay.
  • the signal may be direct (increased if the amount of analyte increases) or inverse (decreased raw signal if the amount of analyte increases).
  • the signal may be absolute (in one state, there is no detectable raw signal at all) or relative (a change in the level of the raw signal, or of the rate of change in the level of the raw signal).
  • the signal may be discrete (yes or no, depending on the level of the raw signal relative to, some threshold) or continuous in value.
  • the signal may be simple (based on a single raw signal) or composite (based on a plurality of raw signals).
  • the detectable raw signal may be one which is visually detectable, or one detectable only with instruments. Possible raw signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and precipitation or agglutination of a component or product.
  • the raw signal may be monitored manually or automatically.
  • a label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, or an agglutinable particle.
  • One diagnostic reagent is a conjugate, direct or indirect, or covalent or noncovalent, of a label with a binding molecule of the invention.
  • the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or autoradiography.
  • Isotopes which are particularly useful for the purpose of the present invention are 3 H, 125 1, 131 1, 35 S, 14 C, and, preferably,
  • fluorescent labeling compounds fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • fluorescence-emitting metals such as 125 Eu, or others of the lanthanide series, may be attached to the binding protein using such metal chelating groups as diethylenetriaminepentaacetic acid (DTP A) of ethylenediamine-tetraacetic acid (EDTA).
  • DTP A diethylenetriaminepentaacetic acid
  • EDTA ethylenediamine-tetraacetic acid
  • the binding molecules also can be detectably labeled by coupling to a chemilummescent compound, the presence of the chemiluminescent compound is then determined by detecting the presence ofiziuinescence that arises during the course of a chemical reaction after a suitable reactant is provided.
  • chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
  • Bioluminescent compound may be used to label the binding molecule.
  • Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence.
  • Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
  • Enzyme labels such as horseradish peroxidase and alkaline phosphatase, are preferred.
  • the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.
  • Assays may be divided into two basic types, heterogeneous and homogeneous.
  • heterogeneous assays the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label.
  • homogeneous assays the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.
  • a target-binding molecule of the present invention may be used diagnostically in the same way that a target-binding antibody is used.
  • the sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate.
  • the sample conceivably could be (or derived from) a food or beverage, a pharmaceutical or diagnostic composition, soil, or surface or ground water.
  • a biological fluid or tissue it may be talcen from a human or other mammal, vertebrate or animal, or from a plant.
  • the preferred sample is blood, or a fraction or derivative thereof.
  • the binding molecule is insolubilized by coupling it to a macromolecular support, and target in the sample is allowed to compete with a known quantity of a labeled or specifically labelable target analogue.
  • the conjugate of the binding molecule to a macromolecular support is another diagnostic agent within the present invention.
  • the "target analogue” is a molecule capable of competing with target for binding to the binding molecule, and the term is intended to include target itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the target analogue from authentic target.
  • the solid and liquid phases are separated, and the labeled target analogue in one phase is quantified. The higher the level of target analogue in the solid phase, i.e., sticking to the binding molecule, the lower the level of target analyte in the sample.
  • both an insolubilized target-binding molecule, and a labeled target-binding molecule are employed.
  • the target analyte is captured by the insolubilized target-binding molecule and is tagged by the labeled target-binding molecule, forming a tertiary complex.
  • the reagents may be added to the sample in either order, or simultaneously.
  • the target-binding molecules may be the same or different, and only one need be a target-binding molecule according to the present invention (the other may be, e.g., an antibody or a specific binding fragment thereof).
  • the amount of labeled target- binding molecule in the tertiary complex is directly proportional to the amount of target analyte in the sample.
  • a label may be conjugated, directly or indirectly (e.g., through a labeled anti- target-binding molecule antibody), covalently (e.g., with SPDP) or noncovalently, to the target-binding molecule, to produce a diagnostic reagent.
  • the target binding molecule may be conjugated to a solid-phase support to form a solid phase (“capture") diagnostic reagent.
  • Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite.
  • the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
  • the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target.
  • the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
  • the surface may be flat such as a sheet, test strip, etc.
  • Analyte-binding molecules can be used for in vivo imaging.
  • Radio-labelled binding molecule may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting devices.
  • the preferred dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as a guide.
  • the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study.
  • the radio- labelled binding molecule has accumulated.
  • the amount of radio-labelled binding molecule accumulated at a given point in time in relevant target organs can then be quantified.
  • a particularly suitable radio-detecting device is a scintillation camera, such as a gamma camera.
  • a scintillation camera is a stationary device that can be used to image distribution of radio-labelled binding molecule.
  • the detection device in the camera senses the radioactive decay, the distribution of which can be recorded.
  • Data produced by the imaging system can be digitized.
  • the digitized information can be analyzed over time discontinuously or continuously.
  • the digitized data can be processed to produce images, called frames, of the pattern of uptake of the radio-labelled binding protein in the target organ at a discrete point in time. In most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in target organs over time.
  • a time-activity analysis of the data will illustrate uptake through clearance of the radio-labelled binding molecule by the target organs with time.
  • the radioisotope must be selected with a view to obtaining good quality resolution upon imaging, should be safe for diagnostic use in humans and animals, and should preferable have a short physical half-life so as to decrease the amount of radiation received by the body.
  • the radioisotope used should preferably be pharmacologically inert, and, in the quantities administered, should not have any substantial physiological effect.
  • the binding molecule may be radio-labelled with different isotopes of iodine, for example 123 1, 125 I, or 131 I (see for example, U. S. Patent 4,609,725).
  • the extent of radio- labeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e., a diiodinated binding molecule will result in twice the radiation count of a similar monoiodinated binding molecule over the same time frame).
  • radioisotopes other than 125 I for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances require). Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred radio-labels are for example, 99m Tc, 67 Ga, 68 Ga, 90 Y, ⁇ In, 113m In, 123 1, 186 Re, 188 Re, or 211 At.
  • the radio-labelled binding molecule may be prepared by various methods. These include radio-halogenation by the chloramines - T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography), for example as described by J. Gutkowska et al. in "Endocrinology and Metabolism Clinics of America" (1987) 16:183. Other known method of radio-labelling can be used, such as IODOBEADSTM. There are a number of different methods of delivering the radio-labelled binding molecule to the end-user. It may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal.
  • the binding molecules of the present invention may also be used to purify target from a fluid, e.g., blood.
  • a solid-phase support Such supports include those already mentioned as useful in preparing solid phase diagnostic reagents.
  • Peptides in general, can be used as molecular weight markers for reference in the separation or purification of peptides by electrophoresis or cliromatography. In many instances, peptides may need to be denatured to serve as molecular weight markers.
  • a second general utility for peptides is the use of hydrolyzed peptides as a nutrient source. Hydrolyzed peptide are commonly used as a growth media component for culturing microorganisms, as well as a food ingredient for human consumption. Enzymatic or acid hydrolysis is normally carried out either to completion, resulting in free amino acids, or partially, to generate both peptides and amino acids.
  • enzymatic hydrolysis does not remove non-amino acid functional groups that may be present.
  • Peptides may also be used to increase the viscosity of a solution.
  • the peptides of the present invention may be used for any of the foregoing purposes, as well as for therapeutic and diagnostic purposes.
  • Any method of identifying peptides, and particularly those methods that select for peptides that bind at biologically relevant sites of the target receptor, may be used in the present invention. See, for example, Hyde-DeRuyscher, R. et al. Chem Biol 7:17-25. (1999), herein incorporated by reference in its entirety.
  • phage display techniques were performed using the ligand binding domain of the androgen receptor. Affinity selection of phage-displayed peptides was carried out basically as described by Sparks et. al. (Sparks AB, Adey NB, Cwirla S, Kay BK. (1996) in Phage Display of Peptides and Proteins, A Laboratory Manual, eds. Kay, B. K., Winter, J. & McCafferty, J. (Academic, San Diego), pp. 227-253), which is herein incorporated by reference in its entirety.
  • biotinylated target protein was immobilized in a streptavidin-coated microtiter well.
  • M13 phage particles distributed among 21 libraries displaying a total of greater than 2x10 10 different random or biased amino acid sequences were added to the immobilized target protein and incubated for 3 hrs at 25°C. Unbound phage were washed away and the bound phage were eluted using pH 2 glycine. The eluted phage were amplified by infecting E. coli cells. The amplified phage were then added to immobilized target protein and the cycle of affinity selection was repeated.
  • Enrichment of phage displaying target-specific peptides was monitored after each round of affinity selection using an anti-M13 antibody conjugated to horseradish peroxidase in an ELISA-type assay. Pools of phage enriched for target-specific peptides were plated for individual plaques. The plaques were picked, the phage amplified, and the phage tested for target-specific binding versus non-specific binding to various control proteins such as hexokinase, alcohol dehydrogenase, ⁇ -galactosidase, and streptavidin. DNA was prepared from target-specific phage, the DNA sequence of the peptide-encoding region was determined, and the peptide sequence was deduced.
  • the peptide sequences were compared and aligned for common motifs. Phage displaying AR-specific peptides were analyzed for their relative binding affinity for the target protein. The phage were serially diluted over a 100-fold range and tested for binding to the target protein using a phage ELIS A assay. Phage that gave a higher ELIS A signal at a lower dilution displayed peptides with a relatively higher affinity for the target protein. Based on their relative affinity for AR, peptides sequences from different sequence clusters were selected for synthesis. The peptides were synthesized with a 5 amino acid linker sequence and a C- terminal biotin.
  • the method described in this publication comprises three general steps: (1) Screen at least one potential surrogate combinatorial library for members (preferably peptides or nucleic acids) binding to the target protein and hence capable of use as surrogates for the unknown ligand in steps (2) and (3); (2) Screen at least one complementary library, preferably a combinatorial library, (which is not limited to, and may not even include peptides or nucleic acids) for compounds which inhibit the binding of one or more surrogates (e.g., peptides or nucleic acids which bind to the target protein); and (3) Determine whether the inhibitory compound mediates the biological activity of the target protein.
  • a combinatorial library which is not limited to, and may not even include peptides or nucleic acids
  • sequences of the identified peptides are as follows, along with their respective identification numbers.
  • SSRWESLWTGEANRSESR 2598 [SEQ ID NO:31) SRFEALYLDRVTGLHTDTSR 2577 (SEQ ID NO: 32) SRTSQMGAFEWAFRGAESR 2554 ( SEQ ID NO: 54) SSDSSRWELLWGRANGHSR 2563 ( SEQ ID NO: 55) SRFEWMFNLPDGNSR 2557 ( SEQ ID NO: 56) SSRFESMWPECHRSKSCSR 2564 ( SEQ ID NO: 57)
  • SRFGEMWPDRHSSSR 2559 SEQ ID NO:58
  • SSIGRLMFPDLEPSRSFSR 2576 SEQ ID NO: 59
  • SRWMNMWDI DRSSR 2567 SEQ ID NO: 60
  • SRGL DFRA FQEEEHSSR 2566 SEQ ID NO: 61
  • SRFQDMFDSFPSHEFSGSR 2571 SEQ ID NO: 63
  • SRFSAMFWANQADSR 2592 SEQ ID NO: 64
  • SRFTDMFLEETGPSR 2590 SEQ ID NO:65
  • SSWSSLFEYDFPSTVGLSR 2601 [SEQ ID NO: 74) SSEGQLFNR FHHSR 2605 [SEQ ID NO: 75) SRLNCLFSTDSGN SVCSR 2584 [SEQ ID NO:76) SSSPFRSLFSNGDSR 2556 [SEQ ID NO:38) SSPFYTLFAPFPTTSPVSR 2572 [SEQ ID NO : 39 ) SSLFANRFFESVCVGGLCSR 2579 [SEQ ID NO: 40) SSVSRGGW GLWNNEKVSR 2574 [SEQ ID NO: 77)
  • SSFQNFFAAPYMESPLSSR 2608 [SEQ ID NO : 13 ) SRFHSFWEVPESWEAKVSR 2609 [SEQ ID NO : 14) SRFADFFRNEGLGSR 2607 i fcJjbi -j ID NO: 15) SSYNSSNGKFAKFWPTYSR 2610 (SEQ ID NO: 16) SSNTPRFKEYFMQSR 2582 (SEQ ID NO:78) SRAGKFDRFWQEESR 2560 (SEQ ID NO:79)
  • SRFEAFYGVGEEGSVGASR 2570 (SEQ ID NO: 80) SSFDKFYLDEYHGRGYQSR 2565 (SEQ ID NO: 81) SRLSDLVKGAEQCVGCMGSR 2580 (SEQ ID NO: 82)
  • POP peptide-on- plate
  • biotinylated peptide is first immobilized onto a BSA- blocked streptavidin-coated microtiter well, and then Europium-conjugated target protein is allowed to react with the biotinylated peptide.
  • Europium-conjugated protein that remains bound to the immobilized peptide after washing is read via time-resolved fluorescence (TRF).
  • TRF time-resolved fluorescence
  • synthetic peptides derived from peptides 2554 and 2582 were tested for their ability to compete with their own binding and with the binding of other peptides to AR.
  • the test biotinylated-peptide is immobilized onto a blocked streptavidin-coated microtiter well as above.
  • Europium- conjugated AR target protein is incubated with increasing concentrations of competitor peptide.
  • the mixture of target and competitor peptide is added to the wells containing immobilized test peptide.
  • Retained AR target protein is monitored by time-resolved fluorescence and the amount of competition by each peptide quantitated relative to no competitor peptide.
  • Interactions between androgen receptor and peptides selected in phage display can be monitored in vivo using a mammalian two-hybrid system.
  • androgen receptor is expressed as an in-frame, carboxy-terminal fusion to a transcriptional activation domain derived from the herpes simplex virus VP16 protein.
  • the peptide of interest is expressed as an in-frame, carboxy-terminal fusion to the yeast derived GAL4 DNA binding domain.
  • the reporter used to monitor peptide/receptor interactions is a luciferase gene downstream of five consensus GAL4 binding sites. Luciferase activity can be corrected for transfection efficiency by including a ⁇ -galactosidase gene driven by a CMV derived promoter.
  • Cells are seeded in media containing 10% fetal bovine serum to a density of 50- 80% confluency in multi-well plates the day before transfection. In all steps, phenol red free media containing charcoal dextran stripped fetal bovine serum is used as essentially steroid-free media. Transfections are carried out in triplicate using lipofectamine to deliver DNA (ratio: 50 ng pCMV-bgal, 1500 ng 5xGAL-luc3, 900 ng pM-peptide, and 500 ng pVP16-receptor). The transfection media is applied for 6 hours and then removed by aspiration. Media containing test compound dilutions is applied to the cells and they incubate for 18-24 hours. The cells are washed twice with PBS and then lysed in 65 ⁇ l of lysis buffer from Tropix Galacto Light Plus
  • Luciferase and ⁇ -galactosidase activities are determined by luminescence as described by the vendor (Tropix LucScreen and Galacto Light Plus). 20 ⁇ l samples of clarified cell lysate is used in each assay and luminescence determined using an LJL Analyst. The luciferase activities are normalized to the corresponding ⁇ -galactosidase values to generate the steroid-dependent peptide/receptor interactions.
  • Peptide sequences corresponding to those listed above were cloned into mammalian cell expression vectors as Gal4 DNA binding domain fusions.
  • the full length AR was cloned into a mammalian expression vector as an in frame fusion with the VP 16 activation domain. Interactions between peptide and AR are monitored by the increase of a reporter gene (luciferase) under the control of Gal4 response elements. Performing transient transfections in a human hepatocyte cell line, a ligand dependent interaction between peptide and AR can be identified ( Figure 2, panels A and B). The interactions between peptide and AR are dose dependent on the ligand added to the mammalian cell culture.

Abstract

La présente invention concerne un polypeptide se liant au récepteur androgène, lequel polypeptide présente la séquence d'acides aminés Ar-X-X-Z-Ar ou Ser-β-Ar-X-?-?-Ar ou Ser-β-Ar-?-X-?-Ar ou Ser-X-Ar-X-X-?-Ar, dans laquelle Ar est un acide aminé aromatique ; X représente tout acide aminé et Z est un acide aminé hydrophobe (?) ou un acide aminé aromatique (Ar) ; β est un acide aminé basique et Δ est un acide aminé acide. Ladite invention concerne également des méthodes pour analyser la conformation de surface d'une protéine au moyen d'une ou de plusieurs des séquences polypeptidiques susmentionnées, des méthodes d'identification de modulateurs de la fonction protéique au moyen d'une ou de plusieurs des séquences polypeptidiques susmentionnées ainsi que des compositions pharmaceutiques contenant un excipient pharmacologiquement acceptable et une ou plusieurs des séquences polypeptidiques susmentionnées.
PCT/US2004/003774 2003-02-12 2004-02-10 Peptides interagissant avec le recepteur androgne WO2004076473A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44695503P 2003-02-12 2003-02-12
US60/446,955 2003-02-12

Publications (2)

Publication Number Publication Date
WO2004076473A2 true WO2004076473A2 (fr) 2004-09-10
WO2004076473A3 WO2004076473A3 (fr) 2005-03-17

Family

ID=32927463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003774 WO2004076473A2 (fr) 2003-02-12 2004-02-10 Peptides interagissant avec le recepteur androgne

Country Status (1)

Country Link
WO (1) WO2004076473A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094330A1 (fr) * 2006-02-15 2007-08-23 National Institute Of Advanced Industrial Science And Technology Peptide capable d'activer un recepteur pour peptides analogues a la bombesine et son utilisation
EP1916257A1 (fr) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin Mimotopes peptidiques de l'antigène GD2 pour la vaccination contre le cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942430A (en) * 1996-02-16 1999-08-24 Diversa Corporation Esterases
US20030045680A1 (en) * 2001-03-12 2003-03-06 Praecis Pharmaceuticals Inc. Peptidic modulators of the androgen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942430A (en) * 1996-02-16 1999-08-24 Diversa Corporation Esterases
US20030045680A1 (en) * 2001-03-12 2003-03-06 Praecis Pharmaceuticals Inc. Peptidic modulators of the androgen receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOHERTY ET AL.: 'Structure-activity relationships of C-terminal endothelin hexapeptide antagonists' JOURNAL OF MEDICINAL CHEMISTRY vol. 36, no. 18, 03 September 1993, pages 2585 - 2594, XP002983399 *
HE ET AL.: 'The FXXLF motif mediates androgen receptor-specific interactions with coregulators' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 277, no. 12, 22 March 2002, pages 10226 - 10235, XP002983400 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094330A1 (fr) * 2006-02-15 2007-08-23 National Institute Of Advanced Industrial Science And Technology Peptide capable d'activer un recepteur pour peptides analogues a la bombesine et son utilisation
EP1916257A1 (fr) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin Mimotopes peptidiques de l'antigène GD2 pour la vaccination contre le cancer
WO2008049643A2 (fr) * 2006-10-27 2008-05-02 Charite - Universitätsmedizin Berlin Peptides mimotopes gd2, leur fabrication et leur utilisation
WO2008049643A3 (fr) * 2006-10-27 2008-10-23 Charite Universitaetsmedizin Peptides mimotopes gd2, leur fabrication et leur utilisation

Also Published As

Publication number Publication date
WO2004076473A3 (fr) 2005-03-17

Similar Documents

Publication Publication Date Title
JP6814745B2 (ja) ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法
US7842456B2 (en) Reagents, kits and methods for immunodetection of epitopes on molecules
Rothbart et al. Peptide microarrays to interrogate the “histone code”
US20030069395A1 (en) Serum albumin binding moieties
Handl et al. Lanthanide-based time-resolved fluorescence of in cyto ligand–receptor interactions
US20090227468A1 (en) Methods For Immuno-Detection Of Epitopes On Molecules And For Detection Of Interactions Of Molecules Via Fluorescent Dyes
AU2001278901A1 (en) Method of identifying conformation-sensitive binding peptides and uses thereof
EP1644513A2 (fr) Dosage et kits servant a detecter une liaison proteique
WO2004076473A2 (fr) Peptides interagissant avec le recepteur androgne
US8148056B2 (en) Methods of identifying modulators of GPR81 receptors
US7422898B2 (en) Nucleic acid encoding monkey Gpr103
KR101611494B1 (ko) ＰＫＣ－δ 검출용 폴리펩티드 및 이의 용도
WO2009141926A1 (fr) Procédé d'acquisition d'un composé capable d'agir sur le métabolisme du glucose/métabolisme lipidique
KR101187674B1 (ko) 이단 면역 크로마토그래피를 이용한 효소 활성 측정법
EP2020447A1 (fr) Procédé pour l'identification de composés modulant l'expression génique de l'adiponectine
KR101564751B1 (ko) Ｓｏｘ２ 검출용 폴리펩티드 및 이의 용도
US20050260661A1 (en) Assays for the identification of modulators of MHC class II expression
Izumi et al. Functional analysis of Rab27a effector granuphilin in insulin exocytosis
US20170030914A1 (en) Detection of elevated levels of phosphorylated mcm and method of increasing mcm phosphorylation capacity
US20050244829A1 (en) Method of screening insulin resistance inproving drug
Christensen et al. Surrogate Ligand-Based Assay Systems for Discovery of Antibacterial Agents for Genomic Targets
KR20120132455A (ko) ｂｃｌ?２ 단백질 표적 펩타이드 및 이의 이용
JP2010285416A (ja) Ａｄｍ抗体エピトープペプチドおよびその利用
KR20110074210A (ko) ｂｃｌ―２ 단백질 표적 펩타이드 및 이의 이용

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase